David Reisman, MD
Hematology & Oncology · Manchester, NHNPI 1285710152
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,233 and has fallen 97.6% since, to $30 in 2024.
Across 132 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$311
- Novartis$261
- E.r. Squibb & Sons, L.L.C.$177
- Amgen$174
- Merck$165
- Daiichi Sankyo Inc.$132
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,41599%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 16 | $311 |
| Novartis | 16 | $261 |
| E.r. Squibb & Sons, L.L.C. | 10 | $177 |
| Amgen | 11 | $174 |
| Merck | 8 | $165 |
| Daiichi Sankyo Inc. | 6 | $132 |
| Pfizer | 7 | $125 |
| Regeneron Healthcare Solutions, Inc. | 5 | $119 |
| Beigene USA, Inc. | 6 | $111 |
| Johnson & Johnson | 7 | $104 |
| AstraZeneca | 5 | $79 |
| AbbVie | 3 | $74 |
| Sanofi | 3 | $67 |
| Eisai Inc. | 3 | $50 |
| Stemline Therapeutics Inc. | 2 | $42 |
| Adaptive Biotechnologies Corporation | 2 | $39 |
| Genentech USA, Inc. | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Seagen Inc. | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $24 |
| Genmab U.S., Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| AVEO Pharmaceuticals, Inc. | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $20 |
| Octapharma USA, Inc. | 1 | $20 |
| G1 Therapeutics, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Global Blood Therapeutics, Inc. | 1 | $17 |
| Incyte Corporation | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| Exelixis Inc. | 1 | $15 |
| Myovant Sciences Inc. | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
How this compares
$2,441 in reported general payments places this provider in the 85th percentile of 61 hematology & oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 16 | $233,074 |
| ImbruvicaIbrutinib | 14 | $219,338 |
| XareltoRivaroxaban | 12 | $7,485 |
| ValacyclovirValacyclovir Hcl | 13 | $777 |
| Prochlorperazine Maleate | 29 | $509 |
| Tamoxifen Citrate | 27 | $429 |
| Anastrozole | 25 | $417 |
| Dexamethasone | 12 | $342 |
| Ondansetron Hcl | 20 | $217 |
| Prednisone | 28 | $154 |
| Allopurinol | 19 | $118 |
| Lorazepam | 12 | $109 |
| Oxycodone Hcl | 12 | $87 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $111 | $233,07416 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $24 | $219,33814 claims |
| Johnson & JohnsonXarelto | $104 | $7,48512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 61 hematology & oncology providers in New Hampshire.
Other hematology & oncology in Manchester
- Goran BroketaManchester$885
- Amr Elsaman RadwanManchester$794
- Rabia SaleemManchester$740
- Eric BonnemManchester$246
- Laura SalamaManchester$165
- Gabriele SouthgateManchester$65
- Frederick LansiganLebanon$23K
- Parth ShahLebanon$18K
- Nancy ChunNashua$7K
- Amy BessnowDover$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.